总结 对于AML 患者,除了巩固治疗以外,缓解后治疗也变得越来越重要,但与 ALL 和 APL 不同,各维持治疗在 AML 中的成功率有所差异。鉴于 AML 的生物学异质性,维持治疗的选择很应基于患者的 AML 基因组学、缓解状态和移植资格,并考虑额外毒性负担、医院随访和患者生活质量方设计维持治疗。 MD安德森癌症中心正在进行的...
影响因子503分的神刊CA-A Cancer Journal for Clinicians是美国癌症协会的旗舰期刊,近日发表综述“Acute myeloid leukemia management and research in 2025”,通讯作者为MD安德森癌症中心Hagop M. Kantarjian教授,作者回顾了AML的一线和后线疗法,...
NCCN和国内指南推荐IA/DA“7+3”方案(阿糖胞苷联合去甲氧柔红霉素/柔红霉素)作为非APL AML的首选治疗。该方案安全有效,完全缓解率可达70-80%,显著提升生存质量1。它适用于所有适合强化治疗的AML患者,无论预后风险。尽管有新生物制剂,其他治疗方案仍是适合...
与成人患者不同,儿童患者还应考虑长期生活质量和继发性恶性肿瘤的预防。全反式维甲酸(ATRA)治疗急性早幼粒细胞白血病(APL)的疗效及作用机制已非常明确,但尚无关于ATRA用于维持治疗的研究报道。本研究拟通过第二次随机对照试验证实与经典的Ara-C+依托泊苷方案相比,ATRA作为联合应用药物在儿童AML维持治疗中的效果。 CC...
The success of all-trans retinoic acid (ATRA) in treating acute promyelocytic leukemia (APL) has shown the potential of differentiation therapy to improve survival in AML patients. However, this success has not been replicated in other subtypes of AML (Takahashi2021). Therefore, there is a need...
APL: Acute promyelocytic leukemia ATRA: All-trans retinoic acid CLL: Chronic lymphocytic leukemia mCR: Bone marrow CR HiDAC: High dose cytarabine (AraC) HMA: Hypomethylating agent LDAC: Low dose cytarabine ITD: Internal tandem duplication TKD: Tyrosine kinase domain ORR: Overall respo...
Patients and Methods Within the Stanford Leukemia Database, we identified 884 consecutive adult patients between 1993 and 2009 meeting the following criteria: age >=18, newly diagnosed AML (excluding APL), clinical management at Stanford University Medical Center (SUMC), and verified residence ...
leukemia (APL,p = 0.927). In the ELN favorable risk group, 5-year OS was 49% in t-AML vs. 56% in de novo AML (median OS 53.5 vs. 168.4 months,p = 0.714). In patients with t-APL, 5-year OS was 75 vs. 70% in de novo APL (median OS 107.9 vs. 198.3 months,p...
Prognosis of acute myeloid leukemia (AML) patients depends on patient-related features, disease manifestations at the time of presentation, and intrinsic disease-related genetic features, such as cytogenetic abnormalities and driver mutations. Prognostic
Acute promyelocytic leukemia (APL) was excluded in this study. 94 AML patients treated with AZA + VEN for at least one cycle and 20 NC samples were enrolled in this study. Our research was approved by the Institutional Ethics Committee of the First Affiliated Hospital of Wenzhou Medical ...